Immunohistochemistry in hollow urinary tract

1.   Amin MB, Trpkov K, Lopez-Beltran A, Grignon D, Members of the IIiDUPG. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 2014; 38(8): e20-34.

2.   Paner GP, Annaiah C, Gulmann C, et al. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol 2014; 45(7): 1473-1482.

3.   Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARC; 2016.

4.   Bassily NH, Vallorosi CJ, Akdas G, Montie JE, Rubin MA. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol 2000; 113(3): 383-388.

5.   Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000; 13(9): 962-972.

6.   Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000; 13(11): 1186-1191.

7.   Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003; 27(1): 1-10.

8.   Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 2014; 38(1): 13-22.

9.   Tian W, Guner G, Miyamoto H, et al. Utility of uroplakin II expression as a marker of urothelial carcinoma. Hum Pathol 2015; 46(1): 58-64.

10. Cox RM, Magi-Galluzzi C, McKenney JK. Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update. Adv Anat Pathol 2018; 25(6): 387-399.

11. Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol 2014; 45(7): 1466-1472.

12. Comperat E, Camparo P, Haus R, et al. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch 2006; 448(3): 319-324.

13. Oh WJ, Chung AM, Kim JS, et al. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma. J Pathol Transl Med 2016; 50(5): 345-354.

14. Wu XR, Lin JH, Walz T, et al. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem 1994; 269(18): 13716-1324.

15. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol 2000; 113(5): 683-687.

16. Brown HM, Wilkinson EJ. Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma. Hum Pathol 2002; 33(5): 545-548.

17. Hoang LL, Tacha DE, Qi W, et al. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder. Arch Pathol Lab Med 2014; 138(7): 943-9.

18. Li W, Liang Y, Deavers MT, et al. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol 2014; 142(6): 864-871.

19. Smith SC, Mohanty SK, Kunju LP, et al. Uroplakin II outperforms uroplakin III in diagnostically challenging settings. Histopathology 2014; 65(1): 132-138.

20. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992; 19(3): 499-508.

21. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999; 85(11): 2469-2474.

22. Babjuk M, Burger M, Compérat E, et al. Non-muscle-invasive Bladder Cancer.  EAU Guidelines Edn presented at the EAU Annual Congress Copenhagen 2018. Arnhem, The Netherlands: EAU Guidelines Office; 2018.

23. Arias-Stella JA, 3rd, Shah AB, Gupta NS, Williamson SR. CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia. Arch Pathol Lab Med 2018; 142(1): 64-69.

24. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001; 25(8): 1074-1078.

25. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 2003; 16(3): 187-191.

26. Aron M, Luthringer DJ, McKenney JK, et al. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and alpha-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol 2013; 37(12): 1815-1823.

27. Jung S, Wu C, Eslami Z, et al. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. Ann Diagn Pathol 2014; 18(1): 27-32.

28. Asgari M, Nabi Maybodi M, Abolhasani M. Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67. Med J Islam Repub Iran 2016; 30: 400.

29. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996; 78(6): 870-875.

30. McKenney JK. Precursor lesions of the urinary bladder. Histopathology 2019; 74(1): 68-76.

31. Mai KT, Busca A, Belanger EC. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma. Appl Immunohistochem Mol Morphol 2017; 25(7): 505-512.

32. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 2001; 25(3): 356-362.

33. Barbisan F, Santinelli A, Mazzucchelli R, et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 2008; 112(3): 636-644.

34. Garbar C, Mascaux C. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist? Anal Quant Cytol Histol 2011; 33(5): 277-782.

35. Kaymaz E, Ozer E, Unverdi H, Hucumenoglu S. Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis. Indian J Pathol Microbiol 2017; 60(4): 510-514.

36. Cox R, Epstein JI. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am J Surg Pathol 2011; 35(9): 1337-1342.

37. Comperat E, McKenney JK, Hartmann A, et al. Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases. Histopathology 2017; 71(5): 703-710.

38. Beltran AL, Cheng L, Montironi R, et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch 2014; 465(2): 199-205.

39. Volmar KE, Chan TY, De Marzo AM, Epstein JI. Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma. Am J Surg Pathol  2003; 27(9): 1243-1252.

40. Lin O, Cardillo M, Dalbagni G, Linkov I, Hutchinson B, Reuter VE. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases. Mod Pathol 2003; 16(12): 1289-1298.

41. Zhong M, Tian W, Zhuge J, et al. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol 2015; 39(1): 127-131.

42. Oliva E, Young RH. Nephrogenic adenoma of the urinary tract: a review of the microscopic appearance of 80 cases with emphasis on unusual features. Mod Pathol 1995; 8(7): 722-730.

43. Amin W, Parwani AV. Nephrogenic adenoma. Pathol Res Pract 2010; 206(10): 659-662.

44. Mazal PR, Schaufler R, Altenhuber-Muller R, et al. Derivation of nephrogenic adenomas from renal tubular cells in kidney-transplant recipients. N Engl J Med 2002; 347(9): 653-659.

45. McDaniel AS, Chinnaiyan AM, Siddiqui J, McKenney JK, Mehra R. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3. Am J Surg Pathol 2014; 38(12): 1664-1671.

46. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011; 35(6): 816-826.

47. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol 2009; 22(9): 1218-1227.

48. Lopez JI, Schiavo-Lena M, Corominas-Cishek A, et al. Nephrogenic adenoma of the urinary tract: clinical, histological, and immunohistochemical characteristics. Virchows Arch 2013; 463(6): 819-825.

49. Lloyd RV, Blaivas M, Wilson BS. Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullary tissues. Arch Pathol Lab Med 1985; 109(7): 633-635.

50. So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol 2013; 26(10): 1365-1370.

51. Chetty R, Pillay P, Jaichand V. Cytokeratin expression in adrenal phaeochromocytomas and extra-adrenal paragangliomas. J Clin Pathol 1998; 51(6): 477-478.

52. Mai KT, Collins JP, Veinot JP. Prostatic adenocarcinoma with urothelial (transitional cell) carcinoma features. Appl Immunohistochem Mol Morphol 2002; 10(3): 231-236.

53. Gordetsky J, Epstein JI. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall. Am J Surg Pathol 2014; 38(7): 941-945.

54. Mohanty SK, Smith SC, Chang E, et al. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas. Am J Clin Pathol 2014; 142(2): 173-183.

55. Wobker SE, Khararjian A, Epstein JI. GATA3 Positivity in Benign Radiated Prostate Glands: A Potential Diagnostic Pitfall. Am J Surg Pathol  2017; 41(4): 557-563.

56. Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate 2003; 55(2): 111-117.

57. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol  2007; 31(8): 1246-1255.

58. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol 2002; 33(11): 1136-1140.

59. Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol 2006; 125(5): 675-681.

60. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol  2008; 32(3): 461-467.

61. Giannico GA, Ross HM, Lotan T, Epstein JI. Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study. Am J Surg Pathol 2013; 37(9): 1401-1406.

62. Tan HL, Haffner MC, Esopi DM, et al. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol 2015; 28(3): 446-456.

63. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007; 50(4): 472-483.

64. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002; 117(3): 471-477.

65. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64(24): 9209-9216.

66. Rogers CG, Palapattu GS, Shariat SF, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006; 175(6): 2048-2053.

67. Zhang Y, Zhu C, Curado MP, Zheng T, Boyle P. Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease. BJU Int 2012; 109(1): 52-56.

68. Schwartz LE, Khani F, Bishop JA, Vang R, Epstein JI. Carcinoma of the Uterine Cervix Involving the Genitourinary Tract: A Potential Diagnostic Dilemma. Am J Surg Pathol 2016; 40(1): 27-35.

69. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol 2012; 36(10): 1472-1476.

70. Alexander RE, Hu Y, Kum JB, et al. p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol 2012; 25(11): 1526-1533.

71. Piaton E, Casalegno JS, Advenier AS, et al. p16(INK4a) overexpression is not linked to oncogenic human papillomaviruses in patients with high-grade urothelial cancer cells. Cancer Cytopathol 2014; 122(10): 760-769.

72. Golovina DA, Ermilova VD, Zavalishina LE, et al. Loss of Cell Differentiation in HPV-Associated Bladder Cancer. Bull Exp Biol Med 2016; 161(1): 96-98.

73. Schmid SC, Thumer L, Schuster T, et al. Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study. Infect Agent Cancer 2015; 10: 31.

74. Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 2011; 204(2): 217-223.

75. Advenier AS, Casalegno JS, Mekki Y, et al. Genotyping of high-risk human papillomaviruses in p16/Ki-67-positive urothelial carcinoma cells: even a worm will turn. Cytopathology  2015; 26(2): 106-113.

76. Kim SH, Joung JY, Chung J, Park WS, Lee KH, Seo HK. Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation. PloS one. 2014; 9(3): e93525.

77. Pichler R, Borena W, Schafer G, et al. Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot. World J Urol 2015; 33(12): 2145-2151.

78. Cowan M, Springer S, Nguyen D, et al. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Mod Pathol 2016; 29(5): 511-515.

79. Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014; 65(2): 360-366.

80. Pivovarcikova K, Pitra T, Vanecek T, et al. Comparative study of TERT gene mutation analysis on voided liquid-based urine cytology and paraffin-embedded tumorous tissue. Ann Diagn Pathol 2016; 24: 7-10.

81. Vinothkumar V, Arunkumar G, Revathidevi S, et al. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. Tumour Biol 2016; 37(6): 7907-7913.

82. Torenbeek R, Lagendijk JH, Van Diest PJ, Bril H, van de Molengraft FJ, Meijer CJ. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology 1998; 32(1): 20-27.

83. Ellis CL, Chang AG, Cimino-Mathews A, et al. GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. Am J Surg Pathol 2013; 37(11): 1756-1760.

84. Paner GP, McKenney JK, Barkan GA, et al. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls. Am J Surg Pathol 2011; 35(6): 787-798.

85. Wang G, Xiao L, Zhang M, et al. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol 2018; 79: 57-65.

86. Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. Am J Clin Pathol 2015; 144(4): 579-591.

87. Bezerra SM, Lotan TL, Faraj SF, et al. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. Hum Pathol 2014; 45(8): 1682-1687.

88. Jones TD, Kernek KM, Yang XJ, et al. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol 2005; 36(7): 718-723.

89. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol  2000; 13(3): 238-242.

90. Erdem GU, Ozdemir NY, Demirci NS, Sahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin 2016; 32(6): 1013-1021.

91. Kouba E, Cheng L. Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics. Endocr Pathol 2016; 27(3): 188-199.

92. Zheng X, Zhuge J, Bezerra SM, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol 2014; 7: 47.